Evidence map›Paper›PMID 32894464›Full record

ArticleDoklady. Biochemistry and biophysics2020

Relationship between the Expression Level of PSMD11 and Other Proteasome Proteins with the Activity of Ricin and Viscumin.

D V Maltseva, M P Raigorodskaya, O V Tikhonova, E N Knyazev, E A Tonevitsky

Abstract read
PubMed Publisher
In one paragraph

Article in Doklady. Biochemistry and biophysics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 89% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

D V MaltsevaShemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia. dmaltseva@gmail.com.
M P RaigorodskayaScientific Research Center Bioclinicum, Moscow, Russia.
O V TikhonovaInstitute of Biomedical Chemistry, Moscow, Russia.
E N KnyazevShemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia. knyazevevg@gmail.com.
E A TonevitskyDevelopment Fund of the Mendeleev Valley Innovation Science and Technology Center, Moscow, Russia.
Institute of Bioorganic Chemistry · RUBioClinicum (Russia) · RUInstitute of Biomedical Chemistry · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The role of proteasome proteins and proteins of the ERAD system in the cytotoxicity of type II ribosome-inactivating proteins ricin and viscumin was investigated. For this, the cell line of colorectal adenocarcinoma HT29, as well as the HT29-sh002 line obtained on its basis, were used. On the basis on the proteome analysis of these lines and the estimation of the proportion of inactivated ribosomes, it was shown that the contribution of the proteasome to the degradation of the catalytic subunits of toxins is different. The role of the Cdc37 co-chaperone in maintaining the stability of A subunit of viscumin in the cytoplasm is shown.

Indexed as

AdenocarcinomaCell Cycle ProteinsChaperoninsColorectal NeoplasmsCytoplasmHumansProteasome Endopeptidase ComplexRibosome Inactivating Proteins, Type 2RibosomesRicinToxins, BiologicalTumor Cells, CulturedCDC37 protein, humanCell Cycle ProteinsChaperoninsmistletoe lectin IProteasome Endopeptidase ComplexPSMD11 protein, humanRibosome Inactivating Proteins, Type 2RicinToxins, BiologicalCdc37degradationERADHT29MLIproteasomePSMD11ribosome inactivating proteinricinviscumin

Identifiers

PMID32894464
OpenAlexW3084345141

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.